Ozempic, Wegovy, and the Brain's "Wanting" System: What Semaglutide May Mean for Cravings and Alcohol
A few weeks after starting Wegovy, he noticed something he had not expected. The constant background chatter about food had gone quiet. Then, at a friend's barbecue, he realized he had nursed one beer for two hours and did not want another. For years, the second and third drinks had felt automatic. Now the pull simply was not there. He felt relieved, and also a little unsettled. If a weekly injection could change what he wanted, what did that say about the struggles he had blamed on himself?
Many people taking semaglutide, sold as Ozempic and Wegovy, describe experiences like this. Researchers are now studying whether these medications affect not only appetite but the brain's broader reward and motivation systems. This post explores what the science currently shows about semaglutide, "wanting," dopamine, and alcohol, and what these changes can mean psychologically.
What semaglutide is
Semaglutide belongs to a class of medications called GLP-1 receptor agonists. They mimic a natural hormone, glucagon-like peptide-1, that the gut releases after eating. In Canada, Ozempic is approved for type 2 diabetes and Wegovy for chronic weight management. These medications slow digestion, increase feelings of fullness, and act on appetite centres in the brain.
GLP-1 receptors are not limited to the gut and appetite regions, though. They also appear in parts of the brain involved in reward and motivation, which is why researchers began asking whether these medications might influence cravings more broadly.
"Wanting" versus "liking"
To understand what people describe, it helps to separate two parts of reward. Neuroscientists Kent Berridge and Terry Robinson (2016) distinguish "wanting," the motivational pull and urge toward something, from "liking," the actual pleasure of experiencing it. "Wanting" depends heavily on dopamine systems in the brain's reward circuitry, while "liking" relies on smaller, separate systems. In addiction, "wanting" can grow stronger and stronger even when the substance no longer brings much pleasure.
This distinction matters because many people on semaglutide describe a change in wanting more than in liking. Food may still taste good, and a drink may still be enjoyable, but the insistent pull toward the next bite or the next glass fades. People often call this the quieting of "food noise." The term is informal, but it captures an experience many people recognize.
What happens in the brain
Much of what we know about mechanism comes from animal research. A 2026 systematic review found that in animal studies, GLP-1 medications consistently reduced intake of alcohol, nicotine, and other drugs, and that activating GLP-1 receptors in reward regions such as the ventral tegmental area and nucleus accumbens reduced the dopamine release those substances normally trigger (Völker et al., 2026). In simple terms, the substance may produce a smaller "this matters, get more" signal in the brain.
It is important to be precise here. These medications do not shut dopamine off, and the popular idea of "dopamine suppression" oversimplifies what appears to be a more targeted dampening of reward responses. The same review noted that human evidence remains limited and preliminary.
What the research shows about alcohol
Human studies are growing quickly, and results so far are encouraging but early.
In a small randomized trial of 48 adults with alcohol use disorder who were not seeking treatment, low-dose semaglutide over nine weeks reduced the amount of alcohol people drank in a laboratory session, reduced drinks per drinking day, and reduced alcohol craving compared with placebo. It did not significantly change the total number of drinks per calendar day, and the authors highlighted the small sample and short duration (Hendershot et al., 2025).
A large Swedish study followed nearly 228,000 people with alcohol use disorder. Those using semaglutide had a 36% lower risk of hospitalization for alcohol use disorder during periods of use, and those using liraglutide, a related medication, had a 28% lower risk (Lähteenvuo et al., 2025). Because this was an observational study, it cannot prove the medications caused the difference, and the authors called for clinical trials.
In 2026, a Danish trial of 108 adults with both alcohol use disorder and obesity found that adding semaglutide to cognitive behavioural therapy reduced heavy drinking days more than therapy plus placebo over six months (National Institutes of Health, 2026). Both groups improved, which also highlights the value of therapy itself.
Despite this momentum, semaglutide is not approved for treating alcohol use disorder, and research has not yet established who benefits most, at what dose, or for how long.
Beyond food and alcohol
People sometimes report that semaglutide seems to reduce other urges too, such as smoking, shopping, or gambling. In the semaglutide trial above, participants who smoked cigarettes reduced their smoking more than those on placebo, though only a small number of smokers took part (Hendershot et al., 2025). For behaviours like shopping or gambling, evidence so far consists mostly of personal reports, so it is too early to draw conclusions.
Some people also describe a general flattening of enjoyment or motivation. Research on this is limited. Regarding more serious mood concerns, the European Medicines Agency reviewed the evidence in 2024 and concluded that it did not support a causal link between GLP-1 medications and suicidal thoughts or actions (European Medicines Agency, 2024). Even so, anyone who notices changes in mood, motivation, or pleasure while taking these medications should tell their prescriber.
The psychological side of a quieter mind
For many people, reduced cravings bring enormous relief. After years of blaming themselves for a lack of willpower, they discover that biology played a much larger role than they realized. That discovery can reduce shame, and it can be deeply validating.
It can also raise harder questions. If food or alcohol was a primary way of coping with stress, loneliness, or painful emotions, what happens when the urge disappears but the feelings remain? Some people feel unexpectedly exposed, restless, or low. Others notice new habits quietly taking the place of old ones. There can be grief, too, for a familiar comfort or a part of social life that has changed. Questions about identity also come up: "Who am I without this struggle?"
There is also the question of what happens after stopping. Research on weight management suggests that appetite effects tend to fade once the medication ends, and we do not yet know how lasting any effects on alcohol might be. Building other ways of meeting emotional needs while the medication creates some breathing room may help people maintain changes over time.
A note of caution for anyone with a history of disordered eating: appetite-suppressing medications can interact with eating disorder patterns in complex ways, including making restriction easier to hide. If you have experienced an eating disorder, involve both your prescriber and a mental health professional in decisions about these medications.
How therapy can help
Medication can quiet the pull, but it does not address why the pull became so strong in the first place. Therapy can help you understand what food, alcohol, or other behaviours were doing for you, develop other ways of coping with stress and emotion, and navigate the identity shifts, grief, and relief that can accompany these changes. For people using semaglutide as part of alcohol treatment, current evidence suggests therapy and medication may work best together.
Reflection questions worth exploring
These prompts are best explored with a professional rather than used to reach conclusions on your own.
What has changed in what I want since starting this medication?
What feelings tend to show up now that the urge is quieter?
What did food or alcohol used to help me cope with?
Have any new habits started to fill the space?
What would I want my life to look like if I stopped this medication one day?
Support at Vive Wellness Therapy
At Vive Wellness Therapy, we support people navigating the emotional side of medications like Ozempic and Wegovy, from relief and self-discovery to unexpected feelings and questions about identity. Whether you are exploring changes in your relationship with food, alcohol, or yourself, we would be glad to hear from you whenever you feel ready.
References
Berridge, K. C., & Robinson, T. E. (2016). Liking, wanting, and the incentive-sensitization theory of addiction. American Psychologist, 71(8), 670–679. https://doi.org/10.1037/amp0000059
European Medicines Agency. (2024, April 12). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024. https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Dermody, S. S., Prince, M. A., Jordan, R., McKee, S. A., Fletcher, P. J., Claus, E. D., & Klein, K. R. (2025). Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 82(4), 395–405. https://doi.org/10.1001/jamapsychiatry.2024.4789
Lähteenvuo, M., Tiihonen, J., Solismaa, A., Tanskanen, A., Mittendorfer-Rutz, E., & Taipale, H. (2025). Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry, 82(1), 94–98. https://doi.org/10.1001/jamapsychiatry.2024.3599
National Institutes of Health. (2026). Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking [News release]. https://www.nih.gov/news-events/news-releases/adding-weekly-glp-1-cognitive-behavioral-therapy-further-reduces-heavy-drinking
Völker, K. M., Prechtl, B. L. H., Bormann, N. L., & Choi, D. S. (2026). The potential role of GLP-1 receptor agonists in substance use disorders: A systematic review. Frontiers in Pharmacology, 16, 1702448. https://doi.org/10.3389/fphar.2025.1702448
This article is provided by Vive Wellness Therapy for general informational and educational purposes only. It is intended to be used alongside professional therapy and medical care and is not a substitute for assessment, diagnosis, or treatment by a qualified health professional. It does not constitute medical advice about starting, stopping, or changing any medication; please speak with your prescriber. Research on GLP-1 medications is evolving rapidly, and information in this article may become outdated or contain inaccuracies. For support with eating concerns, the National Eating Disorder Information Centre (NEDIC) offers a free Canadian helpline at 1-866-633-4220 and live chat at nedic.ca. If you are in crisis or thinking about suicide, call or text 9-8-8 (Suicide Crisis Helpline, available 24/7 across Canada; in Quebec, calls connect to 1-866-APPELLE). If you or someone else is in immediate danger, call 9-1-1 or go to your nearest emergency department.
